Category: Biotechnology company
Quick infos Headquarters: Bothell, Washington, United States Trade prices Volume: 5.0M Market Cap: 26B Prev closed: Open: 141.71 High: 143.42 Low: 139.65 52 week low: 120.99 52 week high: 192.79 Dividends: No Dividends Next ER: April 28, 2022 After Market Closes
About the Company Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
Earnings History Date EPS / Forecast Revenue / Forecast July 28, 2022 April 28, 2022 -0.74 / -0.9964426.46M / 400.08MBeat! February 9, 2022 -0.95 / -0.8301429.85M / 402.16MBeat! October 28, 2021 -1.61 / -0.5758424.06M / 385.13MBeat! July 29, 2021 -0.47 / -0.6122388.48M / 354.32MBeat! view more
Historical Data Date Price Open High Low Vol Change ER Apr 29, 2022 131.01 136.32 137.01
130.20
1.54M 0.60% Apr 28, 2022 130.23 130.54 130.92
125.25
1.62M -0.16% Apr 27, 2022 130.44 132.12 133.99
130.33
1.13M -0.87% Apr 26, 2022 131.59 138.13 139.45
131.44
986.01K -5.02% Apr 25, 2022 138.54 137.61 139.54
136.71
989.02K 0.39% Apr 22, 2022 138.00 140.89 142.11
137.66
709.24K -2.43% Apr 21, 2022 141.44 143.80 146.06
141.08
546.85K -1.7% Apr 20, 2022 143.89 145.07 145.15
142.67
475.43K -0.28% Apr 19, 2022 144.29 143.09 146.56
143.00
435.28K -0.07% Apr 18, 2022 144.39 149.56 149.89
143.64
464.20K -3.56% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company ISIN: US8125781026 CUSIP: 812578102 Founded:15 July 1997 Employees:890 News
Integral Health Asset Management, LLC Buys McKesson Corp, Centene Corp, Abbott Laboratories, ... finance.yahoo.com Feb 10, 2022 1:38 pm Seagen sets 2022 guidance below expectations despite Q4 revenue beat seekingalpha.com Feb 10, 2022 5:30 am Seattle Genetics GAAP EPS of -$0.95 misses by $0.11, revenue of $429.9M beats by $28.23M seekingalpha.com Feb 10, 2022 5:05 am
Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates finance.yahoo.com Feb 9, 2022 5:15 pm Seattle Genetics Q4 2021 Earnings Preview seekingalpha.com Feb 9, 2022 6:35 am
Sivik Global Healthcare LLC Buys SPDR Biotech ETF, Anthem Inc, Universal Health Services Inc, ... finance.yahoo.com Feb 8, 2022 9:38 am Seattle Genetics (SGEN) Q4 2020 Earnings Call Transcript fool.com Jan 31, 2022 5:31 am
North Star Asset Management Inc Buys Navient Corp, Intuitive Surgical Inc, Catalent Inc, Sells ... finance.yahoo.com Feb 7, 2022 9:38 pm Seagen's Adcetris combo improves survival of blood cancer patients in phase 3 trial seekingalpha.com Feb 4, 2022 1:50 am
ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma finance.yahoo.com Feb 3, 2022 8:00 am Seagen upgraded at Morgan Stanley on valuation and upcoming catalysts seekingalpha.com Feb 1, 2022 4:58 am
Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib) in Patients with HER2-Positive Breast Cancer with Brain Metastases finance.yahoo.com Jan 31, 2022 6:00 pm
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer finance.yahoo.com Jan 31, 2022 5:03 pm
Seagen Reports Fourth Quarter and Full Year 2020 Financial Results finance.yahoo.com Jan 31, 2022 4:02 pm
Seagen Reports First Quarter 2021 Financial Results finance.yahoo.com Jan 31, 2022 4:02 pm
Seagen Reports Second Quarter 2021 Financial Results finance.yahoo.com Jan 31, 2022 4:02 pm
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer finance.yahoo.com Jan 31, 2022 4:00 pm
Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy finance.yahoo.com Jan 31, 2022 2:15 pm
Seagen (SGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y finance.yahoo.com Jan 31, 2022 10:28 am
Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer finance.yahoo.com Jan 31, 2022 8:00 am This company doesn't provide a dividend.
Key Persons CEO : Clay B. Siegall, PhD CFO : Todd E. Simpson Talk about Seattle Genetics below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
investor.seattlegenetics.com If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Homepage: seattlegenetics.com Consensus
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.
